CN1548145A - Medicine composition containing epimedium extract - Google Patents
Medicine composition containing epimedium extract Download PDFInfo
- Publication number
- CN1548145A CN1548145A CNA2004100344566A CN200410034456A CN1548145A CN 1548145 A CN1548145 A CN 1548145A CN A2004100344566 A CNA2004100344566 A CN A2004100344566A CN 200410034456 A CN200410034456 A CN 200410034456A CN 1548145 A CN1548145 A CN 1548145A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba epimedii
- pollen
- polysaccharide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention compounds epimedium flavone and polysaccharide extracted from epimedium plant with ginseng, pollen, astragalus root and phellodendron bark extractive to prepare medicine for treating prostatic hyperplasia and prostatitis. The clinical experiment proves the obvious curative effect and no toxic side effect.
Description
The application is that application number is dividing an application of 02148571.2 application for a patent for invention, and the applying date of original application is December in 2002 18 days, and its name is called " Herba Epimedii extract of treatment prostate hyperplasia and the application in the preparation medicine thereof ".
Technical field
The present invention relates to treat the Herba Epimedii extract and the application in the preparation medicine thereof of prostate hyperplasia, be specially epimedium flavone and polysaccharide composition and carrier or other Chinese medicine extract assembly, preparation treatment prostate hyperplasia and prostatitic medicine.
Background technology
Herba Epimedii is Berberidaceae (Berberidaceae) Epimedium (Epimedium) plant barrenwort, Herba Epimedii Epimedium brevicornum is arranged, arrow leaf Herba Epimedii E.sagittatum, pubescence Herba Epimedii E.pubescens, Epimedium wushanense E.wushanense, and the dry aerial parts of Herba Epimedii E.koreanum.It has the effect of kidney invigorating and YANG supporting, bone and muscle strengthening and wind-damp dispelling, is used for the treatment of effects such as impotence and seminal emission, muscles and bones flaccidity are soft, rheumatic arthralgia.Herba Epimedii mainly contains chemical constituents such as flavone, polysaccharide, lignanoid and alkaloid.Clinical practice and pharmacological evaluation report think that epimedium flavone constituents or polysaccharide composition have the treatment cardiovascular disease, strengthen body immunity, adjusting sexual function, treatment osteoporosis and antidotal effect.But these clinical and pharmacological evaluation all are that its flavone and polysaccharide are studied respectively individually so far.Astragalus polysaccharides has pharmacological action widely, can obviously improve body immunity, and the Radix Astragali per ton or Radix Astragali leftover bits and pieces all can extract 65-85kg astragalus polysaccharides or astragalus polysaccharides highly finished product 32-42kg (Chinese colleges and universities-business cooperation network).
Summary of the invention
The technical problem to be solved in the present invention provides the Pharmaceutical composition of a kind of Herba Epimedii effective site assembly, it can have synergistic Chinese medicine extract assembly with conventional carrier and/or some other, preparation treatment prostate hyperplasia and prostatitic pharmaceutical composition, it should be evident in efficacy, and have no side effect substantially, especially meet the requirement of old man's medication and long-term prescription.
For solving the problems of the technologies described above, the invention provides following technical proposals.
A kind of pharmaceutical composition for the treatment of prostate hyperplasia is characterized in that: contain the part of 2-8 by weight of extracting in the barrenwort: total flavones of 8-2 part and polysaccharide; Flavones content is counted 20-90% by weight in the total flavones; The molecular weight ranges of polysaccharide is 1000 to 700000.
In the described pharmaceutical composition, the proportioning of Herba Epimedii total flavones and polysaccharide can be 3-6 part by weight: 7-4 part; The content of icariine in the total flavones and icariine I is counted 10-90% by weight; The scope of the molecular weight of polysaccharide is 45000 to 620000.
Herba Epimedii extract in the aforementioned pharmaceutical composition prepares with following method:
Get epimedium herb, with the extraction with aqueous solution that contains the 60-95% organic solvent, macroporous adsorptive resins D101 or D140 on the residue behind the extracting solution reclaim under reduced pressure organic solvent, water and ethanol mixed solvent gradient elution, collect 30-85% ethanol liquid part, reclaim under reduced pressure, the dry total flavones that gets, flavones content is counted 20-90% by weight in the total flavones;
Get the extraction with aqueous solution Herba Epimedii medicinal residues later of 60-95% organic solvent, use water extraction, the condensed water extracting solution adds ethanol, makes to contain alcohol and measure and reach 70-85%, leaves standstill, filter polysaccharide crude;
Get polysaccharide crude water-soluble after, add chloroform: n-butyl alcohol is 3-6 by volume: 1 part mixed liquor, filtering protein, filtrate is 1000 ultrafilter membrane ultrafiltration with molecular weight, remove the composition of molecular weight below 1000, concentrated solution continues concentrate drying, gets epimedium brevicornum polysaccharide, and its molecular weight ranges is 1000 to 700000;
With Herba Epimedii total flavones and polysaccharide 2-8 part by weight: the proportioning of 8-2 part is mixed.
In the preparation method of the Herba Epimedii extract in the described pharmaceutical composition, Herba Epimedii extracts the aqueous solution of used 60-95% organic solvent, and wherein organic solvent is ethanol, acetone, isopropyl alcohol and/or methanol; The proportioning of Herba Epimedii total flavones and polysaccharide is counted 3-6 part by weight: 7-4 part.
In the preparation method of the Herba Epimedii extract in the described pharmaceutical composition, the content of icariine and icariine I is counted 10%-90% by weight in the total flavones; In the epimedium brevicornum polysaccharide preparation method, polysaccharide crude can be water-soluble once more, adds ethanol, makes to contain the alcohol amount and reach 70-85%, leaves standstill, and leaching polysaccharide crude, the molecular weight of polysaccharide are 45000 to 620000.
Aforementioned pharmaceutical composition is characterized in that: the proportioning of Herba Epimedii total flavones and polysaccharide is counted 3: 8 parts, 4: 6 parts, 5: 5 parts, 6: 4 parts or 7: 3 parts by weight; It can mix with pharmaceutically acceptable carrier or adjuvant.
A kind of treatment prostate hyperplasia and prostatitic pharmaceutical composition is characterized in that: contain Radix Ginseng, pollen, the Radix Astragali, Cortex Phellodendri and Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class.
This compound medicament composition, it is characterized in that: by weight, the Radix Astragali extract 1-4 part that contain Radix Ginseng extract 1-6 part of 6-10% ginsenoside, the pollen that contains the 10-20% flavone or pollen extract 1-8 part, contains 3-5% astragaloside and 20-30% astragalus polysaccharides and the Cortex Phellodendri extract 1-6 part that contains the 10-15% berberine, flavones content is Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class 4-16 part of 20-90%.
Described compound medicament composition is characterized in that: by weight, contain Radix Ginseng extract 1-2 part, pollen or pollen extract 2-4 part, Radix Astragali extract 1-2 part, Cortex Phellodendri extract 1-2 part, Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class 5-10 part.
Aforementioned compound medicament composition is characterized in that: can mix with pharmaceutically acceptable carrier or adjuvant, make various oral formulations.
The preparation method that Herba Epimedii extract is more detailed is described below.
With the Folium Epimedii coarse powder with the extraction with aqueous solution of 60-95% organic solvent 1-4 time, each consumption that extracts solvent is 6-10ml/g, extraction time 1-3 hour, filter merge extractive liquid,, reclaim under reduced pressure organic solvent, aqueous solution add in the macroporous adsorptive resins (as D101 or D140), water and ethanol mixed solvent eluting, collect 30%-85% ethanol liquid part, reclaim under reduced pressure, the dry A part that gets.A extracting section thing is total flavones (is crude flavonoid powder, or flavone crude product), and wherein flavones content is 20-90%, and the content of icariine and icariine I is 10-90% in the total flavones.
Get the medicinal residues after the Folium Epimedii coarse powder is used the extraction with aqueous solution of 60-95% organic solvent, with water extraction 3 times, the consumption of water is 6-10ml/g, extraction time 1-2 hour, filters merging filtrate, concentrate, add ethanol, make to contain the alcohol amount and reach 70-85%, stir evenly, static 12-24 hour, filter and obtain precipitate.Can repeat refining 3 times as needs, get the brownish red polysaccharide crude.Crude polysaccharides is dissolved in 500 ml waters, add chloroform: n-butyl alcohol (3～6: 1) mixed solvent 100-200 milliliter, filtering protein, this aqueous solution molecular weight is 1000 ultrafilter membrane ultrafiltration, remove the composition of molecular weight below 1000, concentrated solution continues concentrate drying, must make with extra care epimedium brevicornum polysaccharide part B.Polysaccharide molecular weight is 1000 to 700000, and polysaccharide part assay method has routinely been identified EPS-1 and two components of EPS-2, and its molecular weight is respectively 45000 and 620000; Polysaccharide is made up of fucose, rhamnose, arabinose, xylose, mannose, glucose, seven kinds of monosaccharide of galactose.In addition, the present invention has also identified four polysaccharide components, and its molecular weight is respectively: 3400,25000,45000 and 520000.
A part flavonoid mixes by a certain percentage with B part polysaccharide, obtains required Herba Epimedii extract, experimental results show that the A part with good efficacy is 2: 8 with B weight ratio partly; 3: 7; 4: 6; 5: 5; 6: 4; 7: 3 and 8: 2.
Clinical and experimental study shows: the pharmaceutical composition that contains epimedium flavone and the certain proportioning of epimedium brevicornum polysaccharide of the present invention has treatment benign prostatauxe disease, and it is for benign prostatauxe, and total effective rate reaches 93.7%.This group patient clinical symptoms integration descends significantly (P＜0.01), and quality of life significantly improves, and mainly shows as the nocturia number of times and reduces the improvement of urinating.The urine flow rate significantly improves (P＜0.01), points out to block to some extent to alleviate.The bladder residual urine volume reduces (P＜0.01).PSA (prostate specific antigen) value is controlled preceding (3.31 ± 3.68 μ g/L) and is controlled back (3.03 ± 3.84 μ g/L) and descends to some extent, but not statistically significant.
Clinical and experimental study shows: the compound recipe that Herba Epimedii extract of the present invention and Radix Ginseng extract, pollen and pollen extract, Radix Astragali extract and Cortex Phellodendri extract are formed also has significant curative effect to the treatment prostate hyperplasia chronic prostatitis disease of holding concurrently.This prescription is to benign prostatauxe and chronic prostatitis, and total effective rate reaches 75.0%.This group patient clinical symptoms integration descends significantly (P＜0.01), and quality of life significantly improves, and mainly shows as the nocturia number of times and reduces the improvement of urinating.The urine flow rate significantly improves (P＜0.01), points out to block to some extent to alleviate.The bladder residual urine volume reduces (P＜0.01).PSA (prostate specific antigen) value is controlled preceding (4.41 ± 5.28 μ g/L) and is controlled significantly decline (P＜0.01) of back (1.84 ± 1.07 μ g/L).
Herba Epimedii extract preparation technology of the present invention is simple, active component is simply clear and definite, and have synergistic therapeutic action between active component flavone and the polysaccharide, flavone and polysaccharide corresponding mixture ratio have been promoted this kind coordinating effect, and it is evident in efficacy to be used for the treatment of benign prostatauxe.
Preparation method and the application in preparation treatment benign prostatauxe medicine thereof below in conjunction with the case description Herba Epimedii extract, and the compound recipe of Herba Epimedii extract, Radix Ginseng extract, pollen and pollen extract, Radix Astragali extract and Cortex Phellodendri extract composition, the application in preparation treatment prostate hyperplasia is held concurrently the chronic prostatitis medicine.
The specific embodiment
Flavone of example 1, Herba Epimedii plant not of the same race and determination of polysaccharide
The plant of preparation Herba Epimedii extract comprises: Herba Epimedii Epimedium brevicornum, arrow leaf Herba Epimedii E.sagittatum, pubescence Herba Epimedii E.pubescens, Epimedium wushanense E.wushanense, and the dry aerial parts of Herba Epimedii E.koreanum.Be collected in provinces such as Sichuan, Shaanxi, Hunan, Hubei, Guizhou and Liaoning respectively.Total flavones is wherein measured with the UV method, and icariine (icarrin) and icariine I (icarisid I) measure with the HPLC method and polyoses content adopts the phenolsulfuric acid method to measure.
Measurement result shows, content of total flavone 6-20% wherein, and total polysaccharides content is 13-26%.
| Plant name | The place of production | Content (%) | |||
| Icariine | Icariine I | Total flavones | Total polysaccharides | ||
| Herba Epimedii | Shaanxi | 1.193 | 0.445 | 12.3 | 20.7 |
| Sichuan | 1.088 | 0.794 | 11.6 | 19.0 | |
| Arrow leaf Herba Epimedii | The Hunan | 0.961 | 0.190 | 7.2 | 15.9 |
| Hubei | 0.735 | 0.110 | 6.4 | 13.4 | |
| Guizhou | 3.098 | 0.084 | 18.3 | 26.1 | |
| Epimedium wushanense | Sichuan | 3.343 | 0.094 | 20.1 | 25.6 |
| Guizhou | 2.882 | 0.030 | 8.9 | 20.1 | |
| The pubescence Herba Epimedii | Sichuan | 1.140 | 0.067 | 10.2 | 18.6 |
| Herba Epimedii | Liaoning | 0.890 | 0.104 | 16.9 | 22.5 |
The preparation of example 2, Herba Epimedii extract
Herba Epimedii (Shaanxi collection) leaf coarse powder 500g, extract 3 times (60 ℃) with 3 liter of 60% alcoholic solution, 2 hours extraction times, filter merge extractive liquid,, the reclaim under reduced pressure organic solvent, aqueous solution adds macroporous adsorbent resin (D101 or D140 post, weight in wet base 1000g), with 3 premium on currency eluting, reuse 30%-85% ethanol liquid eluting, the decompression recycling ethanol eluent, dry A extracting section thing (being total flavones or the title crude flavonoid powder) 20g that gets promptly extracts the 1g Herba Epimedii total flavones, (yield 3% in the 25 gram epimedium herbs, flavones content 45.8% after measured, and main component is icariine and time icariine).Medicinal residues after filtering are boiled with 3 premium on currency carry 50 minutes, extracts 3 times, filter merging filtrate, be concentrated into 1 liter, filter, add 95% ethanol, make to contain alcohol and measure and reach 75%, stir evenly, static 12 hours, filtration obtained precipitate.Repeat water-soluble precipitate with ethanol refining 2 times, get brownish red crude polysaccharides (56g).Crude polysaccharides is dissolved in the 500ml water, use chloroform: n-butyl alcohol (5: 1) organic solvent 100ml mixes, the vibration mixing, remove deproteinize, the aqueous solution molecular weight is 1000 ultrafilter membrane ultrafiltration, removes the composition of molecular weight below 1000, and concentrated solution continues concentrate drying, must make with extra care epimedium brevicornum polysaccharide part B (36.5g), promptly the 13.7g epimedium herb extracts the 1g epimedium brevicornum polysaccharide.The molecular weight of polysaccharide is 1000 to 700000.Identified two polysaccharide components of EPS-1 and EPS-2, molecular weight is respectively 45000 and 620000.Polysaccharide is made up of fucose, rhamnose, arabinose, xylose, mannose, glucose, seven kinds of monosaccharide of galactose.In addition, also identified four polysaccharide components, its molecular weight is respectively: 3400,25000,45000 and 520000.
The A part was pressed 2: 8 respectively with B; 3: 7; 4: 6; 5: 5; 6: 4; The weight ratio of 7: 3 and 8: 2 is mixed, and obtains required Herba Epimedii extract.
The plant of preparation Herba Epimedii extract comprises: Herba Epimedii Epimedium brevicornum, arrow leaf Herba Epimedii E.sagittatum, pubescence Herba Epimedii E.pubescens, Epimedium wushanense E.wushanense, and the dry aerial parts of Herba Epimedii E.koreanum.Every kind of plant consumption is 500g, by above-mentioned prepared.Flavones content is 20-90% in the total flavones.The result is as follows for the each several part yield:
| Plant name | The place of production | A part yield | B part yield |
| Herba Epimedii | Shaanxi | 20g，4％ | 37g，7.4％ |
| Sichuan | 10g，3％ | 29g，5.8％ |
| Arrow leaf Herba Epimedii | The Hunan | 12g，2.4％ | 20g，4.0％ |
| Hubei | 8g，1.6％ | 30g，6.0％ | |
| Guizhou | 27g，5.8％ | 39g，7.8％ | |
| Epimedium wushanense | Sichuan | 23g，4.6％ | 42g，8.4％ |
| Guizhou | 16g，3.2％ | 32g，6.4％ | |
| The pubescence Herba Epimedii | Sichuan | 9g，1.8％ | 25g，5.0％ |
| Herba Epimedii | Liaoning | 18g，3.6％ | 28g，5.6％ |
The compound recipe preparation of example 3, Herba Epimedii extract and Radix Ginseng, pollen, the Radix Astragali and Cortex Phellodendri
This compound recipe is made up of by weight mixing following five class components:
(flavone is 40% to Herba Epimedii extract in the total flavones, and icariine is 20% in the total flavones; Polysaccharide is 40%) 5 parts; 1 part of Radix Ginseng extract (content of ginsenoside 6-10%); 2 parts of pollen or pollen extracts (flavones content 10%-20%); 1 part of Radix Astragali extract (more than the astragaloside 3-5%, astragalus polysaccharides 20-30%); 1 part of Cortex Phellodendri extract (berberine 10-15%).
Herba Epimedii extract is pressed method preparation in the example 2.
Radix Ginseng extract (content of ginsenoside 6-10%) preparation method is as follows: 500 gram Radix Ginseng coarse powder, ethanol water 1-2L heating and refluxing extraction with 70% 2-3 time, decompression recycling ethanol, filter, evaporate to dryness filtrate, get Radix Ginseng extract 160 grams, promptly can extract the Radix Ginseng extract of 1 gram content of ginsenoside 6-10% in the 3.1 gram Radix Ginsengs.
Pollen or pollen extract (flavones content 10-20%) preparation method is as follows: 500 gram pollen, the ethanol water 1-2L heating and refluxing extraction with 75% 2-3 time, decompression recycling ethanol, filter, evaporate to dryness filtrate gets pollen extract 126 grams, and promptly 4 gram pollen can extract 1 gram pollen extract.
Radix Astragali extract is (more than the astragaloside 3-5%, astragalus polysaccharides 20-30%) preparation method is as follows: 500 gram radix astragali coarse powder, ethanol water 2-4L heating and refluxing extraction with 75% 2-3 time, decompression recycling ethanol, filter, macroporous adsorbent resin (D101 on the filtrate, 1 kilogram), water and ethanol water gradient elution, collect the ethanol liquid of 30%-85%, concentrate drying gets extract 67 grams (containing astragaloside 4.7%), and promptly the 7.5 gram Radixs Astragali can extract the astragaloside extract that 1 gram contains astragaloside 4.7%.Boil 3 times with the medicinal residues water (1L) behind the 75% ethanol liquid eluting, filtering and concentrating is to 1L, and it is 75-85% that adding ethanol makes ethanol content, and precipitation is refining that polysaccharide part 16 restrains, and promptly 31.3 gram medical materials can extract 1 and restrain astragalus polysaccharides.Saponin is partly partly pressed 7: 3 mixed with polysaccharide, get Radix Astragali extract.
Cortex Phellodendri extract (berberine 10%-15%) preparation method is as follows: 500 gram Cortex Phellodendris are pulverized the ethanol water 1-2L heating and refluxing extraction with 75% 2-3 time, decompression recycling ethanol, filter, evaporate to dryness filtrate gets Cortex Phellodendri extract 96 grams, and promptly 5.2 gram Cortex Phellodendri medical materials can extract 1 gram Cortex Phellodendri extract.
Example 4, studies on acute toxicity
Herba Epimedii extract:
Animal is selected 40 of SD mices (Kunming kind) for use, body weight 20 ± 2g, and male and female half and half, fasting is 16 hours before the experiment, allows it freely drink water.Divide equally 2 groups (n=20), first group disposable gavages Herba Epimedii extract I (A: B is 4: 6 parts; A, B record after mixing: flavones content 40%, icariine 10%, polysaccharide 60%) 6g/kg, second group of disposable Herba Epimedii extract I 9g/kg that gavages observed 7 days, appetite, spontaneous activity, feces, growth promoter and death condition behind the record animals administer.Same experimental implementation, identical dosage, we have observed Herba Epimedii extract II, and (A: B is 6: 4 parts; Record after A, B mix: flavones content 40%, icariine 20%, polysaccharide 40%) and Herba Epimedii extract III (A: B is 7: 3 parts; Record after A, B mix: icariine 60%, polysaccharide 30%) and example 3 Herba Epimedii compound recipes (Herba Epimedii, Radix Ginseng, the Radix Astragali, pollen and Cortex Phellodendri) to the acute toxicity of mice.
The result shows that Herba Epimedii extract I, II, III and example 3 Herba Epimedii compound recipe oral administration are irritated the LD of stomach
50Fail to measure, therefore, the LD of oral medication
50Greater than 9g/kg.
Example 5, clinical and experimental study result
1, the purpose of clinical and experimental study:
1) observes Herba Epimedii extract to definite curative effect of benign prostatauxe and toxicity;
2) observe Herba Epimedii prescription (Herba Epimedii, Radix Ginseng, the Radix Astragali, pollen and Cortex Phellodendri) in the previous examples 3 to prostate hyperplasia the hold concurrently curative effect and the toxic and side effects of chronic prostatitis.
2, patient includes standard in:
1) allly meet simple property prostate hyperplasia, the age is more than 50 years old,
2) prostate hyperplasia companion prostatitis, the age is more than 30 years old,
3) score of symptom and sign is 〉=6 minutes, and accompanies corresponding physics and chemistry to detect unusual in various degree person,
4) prostate hyperplasia companion sexual impotence, premature ejaculation person.
Patient's statistics is as follows:
| Group | The example number | Age (year) | The course of disease (year) | Compressibility dysfunction example number |
| Benign prostatauxe * | ??32 | ??64.90±7.8 | ???11.5±8.7 | |
| Prostate hyperplasia companion chronic prostatitis * * | ??24 | ??42.42±12.1 | ???3.5±3.3 | ????24 |
* benign prostatauxe group Herba Epimedii extract;
* prostate hyperplasia companion chronic prostatitis Herba Epimedii extract prescription (Radix Ginseng, the Radix Astragali, pollen and Cortex Phellodendri)
3, Therapeutic Method
The benign prostatauxe group: (A: B is 6: 4 parts with Herba Epimedii extract; Record after the mixing: flavones content 40%, icariine 20%, polysaccharide 40%).Dosage: 250mg/ grain * 3 * 2 time/day.
The prostate hyperplasia chronic prostatitis group of holding concurrently: with example 3 Herba Epimedii extract compound recipes.Dosage: 250mg/ grain * 3 * 2 time/day.
4, observational technique: integration 〉=6 are minute as the object of observation.Divide equally and see the following form:
Prostate hyperplasia clinical symptoms sign point system
Symptom and sign 0 minute 1 minute 2 minutes 3 minutes
The interrupted one-tenth of urine stream line is urinated drop and is descended, no
Normal urine thin of the situation of urinating or wire
Shape becomes line
The lower abdomen symptom does not have completely vexed sense sensation of fullness distension pain
Second 40-50 51-60 second second＞60, urination time＜40 second
Second urine flow rate＞15ml/ 11-15ml/ second 6-10ml/ second second＜6ml/
Residual urine amount 10ml 10-50ml 50-100ml＞100ml
The normal I degree of prostate hyperplasia hypertrophy II degree hypertrophy III degree hypertrophy
Annotate: prostatic hyperplasia calibration, list of references: Wu Saizhu, gonadal hormone and infirmities of age, front page, Beijing: the 1998.171-189 of China Science Tech Publishing House.
5, criterion of therapeutical effect
Clinic control: cardinal symptom and sign disappear, and integration rate reduces more than 90%, and it is normal that physical and chemical index recovers.
Produce effects: cardinal symptom and sign are most of to disappear, and integration reduces 60-89%, and it is normal that physical and chemical index recovers substantially.
Effectively: cardinal symptom and sign partly alleviate or disappear, and integration reduces 15-59%, and physical and chemical index takes a turn for the better to some extent.
Invalid: cardinal symptom and sign no change, even increase the weight of.
6, toxicity is observed
Routine blood test: observe treatment front and back RBC, Hb, WBC and Plt and change
Routine urinalysis: observe the variation of treatment front and back urine protein and RBC
Liver function: observe the variation of treatment front and back ALT and AST
Renal function: observe the variation of treatment front and back BUN and Cr.
7, statistical disposition
Measurement data is represented with X ± SD pairing t-test handles; Handle between group and check with Ridit.
8, result
1) benign prostatauxe and prostate hyperplasia are held concurrently, and the clinical symptoms integration changes as shown in the table before and after the treatment of two groups of chronic prostatitiss.
Table 1, two groups of prostate hyperplasia clinical symptoms integrations change (X ± SD)
| Grouping | Control preceding integration | Control the back integration | The P value |
| Benign prostatauxe | 12.16±2.42 | 6.26±1.98 | P＜0.01 |
| Benign prostatauxe companion inflammation | 10.42±2.54 | 4.88±2.82 | P＜0.01 |
2) bladder residual urine volume.The urine residual volume of two groups of treatment front and back significantly reduces.
Table 2, two groups of bladder residual urine volumes change (unit: mL, X ± SD)
| Grouping | Before controlling | Control the back integration | The P value |
| Benign prostatauxe | 65.93±60.19 | 37.19±43.05 | P＜0.05 |
| Benign prostatauxe companion inflammation | 45.83±53.48 | 25.41±34.38 | P＜0.05 |
3) urine flow rate.The urine flow rate of two groups of treatment front and back significantly increases.
Table 3, two groups of urine flow rate variation (unit: mL/ second, X ± SD)
| Grouping | Before controlling | Control the back integration | The P value |
| Benign prostatauxe | 4.41±1.44 | 7.74±3.33 | P＜0.01 |
| Benign prostatauxe companion inflammation | 7.02±3.29 | 10.91±5.46 | P＜0.01 |
4) prostate specific antigen (PSA) is measured.The prostate hyperplasia chronic prostatitis group PSA that holds concurrently significantly descends.
Table 4, two groups of PSA change (unit: μ g/L, X ± SD)
| Grouping | Before controlling | Control the back integration | The P value |
| Benign prostatauxe | 3.31±3.68 | 3.03±3.84 | P＞0.05 |
| Benign prostatauxe companion inflammation | 4.41±5.28 | 1.84±1.07 | P＜0.01 |
5) benign prostatauxe and the prostate hyperplasia chronic prostatitis group general curative effect evaluation of holding concurrently
Table 5: benign prostatauxe and the prostate hyperplasia chronic prostatitis group general curative effect evaluation of holding concurrently
| Grouping | The example number | Control | Produce effects | Effectively | Invalid | Effectively total | Total effective rate |
| Loose group | 32 | ?2 | ?12 | ?16 | ?2 | ?30 | 93.8％ |
| The loose inflammation group of holding concurrently | 24 | ?1 | ?6 | ?11 | ?6 | ?18 | 75.0％ |
Two groups of curative effects relatively adopt the Ridit analyzing and processing, and P＜0.05 shows that optimum loose group general curative effect is better than benign prostatauxe companion inflammation group as a result.
Benign prostatauxe and the prostate hyperplasia companion chronic prostatitis group sexual function improving therapeutic evaluation of holding concurrently: in benign prostatauxe and prostate hyperplasia are held concurrently chronic prostatitis group patient, take example 3 Herba Epimedii compound recipes, dosage: 250mg/ grain * 3 * 2 time/day.The sexual impotence symptom that general curative effect is evaluated as 28.6% patient improves; 50% premature ejaculation patient improves.
Clinical and experimental study shows that Herba Epimedii extract is for benign prostatauxe, and total effective rate reaches 93.7%.This group patient clinical symptoms integration descends significantly (P＜0.01), and quality of life significantly improves, and mainly shows as the nocturia number of times and reduces the improvement of urinating.The urine flow rate significantly improves (P＜0.01), points out to block to some extent to alleviate.The bladder residual urine volume reduces (P＜0.01).PSA (prostate specific antigen) value is controlled preceding (3.31 ± 3.68 μ g/L) and is controlled back (3.03 ± 3.84 μ g/L) and descends to some extent, but not statistically significant.
Clinical and experimental study shows, the compound recipe that Herba Epimedii extract and Radix Ginseng extract, pollen and pollen extract, Radix Astragali extract and Cortex Phellodendri extract are formed is to the prostate hyperplasia chronic prostatitis of holding concurrently, and total effective rate reaches 75.0%.This group patient clinical symptoms integration descends significantly (P＜0.01), and quality of life significantly improves, and mainly shows as the nocturia number of times and reduces the improvement of urinating.The urine flow rate significantly improves (P＜0.01), points out to block to some extent to alleviate.The bladder residual urine volume reduces (P＜0.01).PSA (prostate specific antigen) value is controlled preceding (4.41 ± 5.28 μ g/L) and is controlled significantly decline (P＜0.01) of back (1.84 ± 1.07 μ g/L).The patient's effective percentage that is mixed with sexual impotence and premature ejaculation sexual function among this group patient is respectively 28.6% and 50.0%.
In clinical and experimental study, all any toxicity does not appear in the patient, and none example of all routine blood tests, liver function, renal function and routine urinalysis occurs unusual before and after the treatment.
The Herba Epimedii extract active component is simply clear and definite, and preparation method is simple, and technology is fit to suitability for industrialized production, is used to prepare the medicine of benign prostatauxe, and clinical effectiveness is remarkable.
Claims (6)
1, a kind of treatment prostate hyperplasia and prostatitic pharmaceutical composition is characterized in that: contain Radix Ginseng, pollen, the Radix Astragali, Cortex Phellodendri and Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class.
2, pharmaceutical composition according to claim 1 is characterized in that: flavones content is counted 20-90% by weight in the Herba Epimedii total flavones; The molecular weight ranges of epimedium brevicornum polysaccharide is 1000 to 700000.
3, pharmaceutical composition according to claim 2 is characterized in that: the content of icariine and icariine I is counted 10%-90% by weight in the Herba Epimedii total flavones; The molecular weight ranges of epimedium brevicornum polysaccharide is 45000 to 620000.
4, pharmaceutical composition according to claim 1, it is characterized in that: by weight, the Radix Astragali extract 1-4 part that contain Radix Ginseng extract 1-6 part of 6-10% ginsenoside, the pollen that contains the 10-20% flavone or pollen extract 1-8 part, contains 3-5% astragaloside and 20-30% astragalus polysaccharides and Cortex Phellodendri extract 1-6 part, Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class 4-16 part of containing the 10-15% berberine.
5, pharmaceutical composition according to claim 4 is characterized in that: by weight, contain Radix Ginseng extract 1-2 part, pollen or pollen extract 2-4 part, Radix Astragali extract 1-2 part, Cortex Phellodendri extract 1-2 part, Herba Epimedii total flavones and/or epimedium brevicornum polysaccharide class 5-10 part.
6, according to the described pharmaceutical composition of one of claim 1-5, it is characterized in that: it mixes with pharmaceutical carriers or adjuvant, makes various oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410034456 CN1254260C (en) | 2002-12-18 | 2002-12-18 | Medicine composition containing epimedium extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410034456 CN1254260C (en) | 2002-12-18 | 2002-12-18 | Medicine composition containing epimedium extract |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021485712A Division CN1194702C (en) | 2002-12-18 | 2002-12-18 | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548145A true CN1548145A (en) | 2004-11-24 |
| CN1254260C CN1254260C (en) | 2006-05-03 |
Family
ID=34352241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410034456 Expired - Lifetime CN1254260C (en) | 2002-12-18 | 2002-12-18 | Medicine composition containing epimedium extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1254260C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012058957A2 (en) * | 2010-11-05 | 2012-05-10 | 中国人民解放军军事医学科学院毒物药物研究所 | Polysaccharide extracts of epimedium, fractions thereof and uses thereof in vaccine adjuvants |
| CN103613675A (en) * | 2010-11-05 | 2014-03-05 | 中国人民解放军军事医学科学院毒物药物研究所 | Herba epimedii polysaccharide and components thereof as well as use of herba epimedii polysaccharide and components thereof as vaccine adjuvants |
-
2002
- 2002-12-18 CN CN 200410034456 patent/CN1254260C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012058957A2 (en) * | 2010-11-05 | 2012-05-10 | 中国人民解放军军事医学科学院毒物药物研究所 | Polysaccharide extracts of epimedium, fractions thereof and uses thereof in vaccine adjuvants |
| WO2012058957A3 (en) * | 2010-11-05 | 2012-06-28 | 中国人民解放军军事医学科学院毒物药物研究所 | Polysaccharide extracts of epimedium, fractions thereof and uses thereof in vaccine adjuvants |
| CN103613675A (en) * | 2010-11-05 | 2014-03-05 | 中国人民解放军军事医学科学院毒物药物研究所 | Herba epimedii polysaccharide and components thereof as well as use of herba epimedii polysaccharide and components thereof as vaccine adjuvants |
| CN103613675B (en) * | 2010-11-05 | 2016-08-17 | 北京中安佐际生物科技有限公司 | Epimedium brevicornum polysaccharide and component thereof are used for the purposes of vaccine adjuvant with them |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1254260C (en) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100335117C (en) | Chinese medicinal lotion for new-borne baby's removing jaundice | |
| CN1754541A (en) | Steroid saponin pharmaceutical composition and its preparation method and uses | |
| CN1194702C (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN101040924A (en) | Chinese traditional medicine for treating fowl coccidiosis and the preparing method thereof | |
| CN1814149A (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN1771977A (en) | Notoginseng glycol-saponin composition and its prepn and use | |
| CN1254260C (en) | Medicine composition containing epimedium extract | |
| CN101028317A (en) | Use of hypericum japonicum in preparation of medicine against nephritis and renal insufficiency | |
| CN1305480C (en) | Antineoplastic medicinal composition, its preparation method and application | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN1836712A (en) | Pharmaceutical composition for treating sexual disorder and its preparation process | |
| CN1810265A (en) | Total sennoside extract for treating constipation and its extraction process | |
| CN1261143C (en) | Separating preparation process of effective part and active component of influenza virus resisting medicine | |
| CN1631902A (en) | Angelica polysaccharide and its preparation and use | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1237984C (en) | Prepn. method of freezing-drying powder injection for anticancer made of Chinese herb medicines | |
| CN1058170C (en) | Drug for treating sexual impotence | |
| CN101062108A (en) | Medicinal composition for treating dysmenorrhea and preparation process thereof | |
| CN1263490C (en) | Yang reinforcing medicine and its preparation method | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof | |
| CN1281252C (en) | Medicinal composition for treating urinary lithiasis and its preparing method | |
| CN1537570A (en) | Application of Ypsilandra herbs for preparing medicines for treating hemorrhagic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1071073 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041124 Assignee: SHENZHEN BRIGHT FUTURE TECHNOLOGY DEVELOPMENT CO.,LTD. Assignor: BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LTD. Contract record no.: 2015990000378 Denomination of invention: Medicine composition containing epimedium extract Granted publication date: 20060503 License type: Exclusive License Record date: 20150526 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060503 |